Novo Nordisk A-S
Closed
SectorHealthcare
43.06 -2.23
Overview
Share price change
24h
Min
42.9
Max
43.17
Income | -28B 21B |
|---|---|
Sales | -18B 78B |
P/E Sector Avg | 11.45 56.597 |
EPS | 0.96 |
Dividend yield | 3.86 |
Profit margin | 26.742 |
Employees | 66,700 |
EBITDA | -31B 39B |
Dividend yield Sector Avg | 3.86% 2.18% |
|---|
Market Cap | -2.3B 206B |
|---|---|
Previous open | 45.29 |
Previous close | 43.06 |
News Sentiment
By Acuity
62%
38%
276 / 339 Healthcare
Novo Nordisk A-S Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Novo Nordisk A-S Forecast
Sentiment
By Acuity
276 / 339 Healthcare
News Sentiment
Bearish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Novo Nordisk A-S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.